Who is sponsoring NCT03291444?

NCT03291444 is sponsored by Zhujiang Hospital.

What drugs are being tested in NCT03291444?

Interventions in NCT03291444: Chimeric antigen receptor T cells, peptide specific dendritic cell.

What condition does NCT03291444 study?

NCT03291444 studies Leukemia, Acute Lymphocytic (ALL), Leukemia, Acute Myelogenous (AML), Myelodysplastic Syndromes.

Is NCT03291444 still recruiting?

NCT03291444 is currently status unknown. Last updated 15 March 2024.

Last reviewed 2024-03-15 · How we verify

NCT03291444

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS

Status unknown Phase 1 Last updated 15 March 2024

What this trial tests

Phase 1 trial testing Chimeric antigen receptor T cells in Leukemia, Acute Lymphocytic (ALL) in 30 participants. Status unknown.

Timeline

5 May 2018

Primary endpoint
31 December 2024

1 June 2025

Quick facts

Lead sponsor	Zhujiang Hospital
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	5 May 2018
Primary completion	31 December 2024
Estimated completion	1 June 2025
Sites	1 location across China

Drugs / interventions tested

Chimeric antigen receptor T cells — full drug profile →
peptide specific dendritic cell — full drug profile →

Conditions studied

Leukemia, Acute Lymphocytic (ALL) — all drugs for Leukemia, Acute Lymphocytic (ALL) →
Leukemia, Acute Myelogenous (AML) — all drugs for Leukemia, Acute Myelogenous (AML) →
Myelodysplastic Syndromes — all drugs for Myelodysplastic Syndromes →

Sponsor

Zhujiang Hospital

Who can join

Adults 18 to 80, any sex, with Leukemia, Acute Lymphocytic (ALL) or Leukemia, Acute Myelogenous (AML). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this study is to verify the safety and potential effectiveness of CART cells combined with peptide specific dendritic cell in relapsed/refractory leukemia.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions.
Mardiana S, Gill S. · · 2020 · cited 155× · PMID 32435621 · DOI 10.3389/fonc.2020.00697
Research progress on dendritic cell vaccines in cancer immunotherapy.
Yu J, Sun H, Cao W, Song Y, et al · · 2022 · cited 130× · PMID 35074008 · DOI 10.1186/s40164-022-00257-2
CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies.
Testa U, Pelosi E, Castelli G. · · 2019 · cited 114× · PMID 31547472 · DOI 10.3390/cancers11091358
Trial watch: dendritic cell vaccination for cancer immunotherapy.
Sprooten J, Ceusters J, Coosemans A, Agostinis P, et al · · 2019 · cited 107× · PMID 31646087 · DOI 10.1080/2162402x.2019.1638212
CAR-T cell combination therapy: the next revolution in cancer treatment.
Al-Haideri M, Tondok SB, Safa SH, Maleki AH, et al · · 2022 · cited 106× · PMID 36419058 · DOI 10.1186/s12935-022-02778-6
Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML).
Hofmann S, Schubert ML, Wang L, He B, et al · · 2019 · cited 84× · PMID 30736352 · DOI 10.3390/jcm8020200
Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
Marofi F, Rahman HS, Al-Obaidi ZMJ, Jalil AT, et al · · 2021 · cited 64× · PMID 34412685 · DOI 10.1186/s13287-021-02420-8
Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML.
Valent P, Sadovnik I, Eisenwort G, Bauer K, et al · · 2019 · cited 45× · PMID 31470642 · DOI 10.3390/ijms20174233

Verify or expand the search:

Other Zhujiang Hospital trials

Trials by the same sponsor.

NCT07335094 — A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lym · EARLY_PHASE1 · not yet recruiting
NCT07469072 — Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in t · Phase 2 · recruiting
NCT07455149 — An Observational Clinical Study on the Association of Intestinal Ruminococcus Gnavus and Its Derived Biogenic Amines Wit · not yet recruiting
NCT07457099 — Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral a · not yet recruiting
NCT07454421 — Racecadotril for Organ Injury in Sepsis Patients · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03291444 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhujiang Hospital
Last refreshed: 15 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03291444.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing